Mark G Foletta
CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-08-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DXCM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 500
DALLAS, TX 75019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DXCM | Director | 57,183 | $79.68 | $4.56M | -$5.96M | 39 | 2026-08-04 |
| AMN | Director | 41,515 | $37.54 | $1.56M | -$1.20M | 21 | 2026-06-17 |
| ENTA | Director | — | $11.30 | — | $0 | 7 | 2026-03-13 |
| Forte Biosciences, Inc. (TOCA) Delisted | EVP & Chief Financial Officer | 1,003 | — | — | $71.5K | 7 | 2019-10-04 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 683 | $8.16 | $5.6K | $76.4K | 7 | 2017-12-06 |
| AMN HEALTHCARE SERVICES INC (AHS) Delisted | Director | 5,532 | — | — | $0 | 4 | 2016-04-22 |
| BIOCEPT INC (BIOC) Delisted | Interim CFO | — | $0.43 | — | $0 | 1 | 2015-09-02 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 2 | 2014-11-12 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | SVP, Chief Financial Officer | 81,344 | — | — | -$1.48M | 25 | 2012-07-26 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 6 | 2011-05-27 |
Recent Filings · Page 8 of 13
130 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-02 | Forte Biosciences, Inc. (TOCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-14 | Forte Biosciences, Inc. (TOCA) Delisted | Other (J) | +2,500 | $21.2K | EDGAR |
| 2017-12-06 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | +71,910 | $64.0K | EDGAR |
| 2017-11-29 | DXCM | Sell (S) | −2,500 | -$137.4K | EDGAR |
| 2017-11-28 | AMN | Sell (S) | −2,500 | -$117.6K | EDGAR |
| 2017-06-14 | AMN | Sell (S) | −1,500 | -$55.1K | EDGAR |
| 2017-06-05 | DXCM | Grant (A) | +4,952 | $5 | EDGAR |
| 2017-06-02 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-31 | Forte Biosciences, Inc. (TOCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-21 | Forte Biosciences, Inc. (TOCA) Delisted | Buy (P) | +5,000 | $50.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.